Back to Search Start Over

CD40 Ligand Deficiency in Latin America: Clinical, Immunological, and Genetic Characteristics.

Authors :
França TT
Barreiros LA
Salgado RC
Napoleão SMDS
Gomes LN
Ferreira JFS
Prando C
Weber CW
Di Gesu RSW
Montenegro C
Aranda CS
Kuntze G
Staines-Boone AT
Venegas-Montoya E
Becerra JCA
Bezrodnik L
Di Giovanni D
Moreira I
Seminario GA
Raccio ACG
Dorna MB
Rosário-Filho NA
Chong-Neto HJ
de Carvalho E
Grotta MB
Orellana JC
Dominguez MG
Porras O
Sasia L
Salvucci K
Garip E
Leite LFB
Forte WCN
Pinto-Mariz F
Goudouris E
Nuñez MEN
Schelotto M
Ruiz LB
Liberatore DI
Ochs HD
Cabral-Marques O
Condino-Neto A
Source :
Journal of clinical immunology [J Clin Immunol] 2022 Apr; Vol. 42 (3), pp. 514-526. Date of Electronic Publication: 2022 Jan 04.
Publication Year :
2022

Abstract

CD40 ligand (CD40L) deficiency is a rare inborn error of immunity presenting with heterogeneous clinical manifestations. While a detailed characterization of patients affected by CD40L deficiency is essential to an accurate diagnosis and management, information about this disorder in Latin American patients is limited. We retrospectively analyzed data from 50 patients collected by the Latin American Society for Immunodeficiencies registry or provided by affiliated physicians to characterize the clinical, laboratory, and molecular features of Latin American patients with CD40L deficiency. The median age at disease onset and diagnosis was 7 months and 17 months, respectively, with a median diagnosis delay of 1 year. Forty-seven patients were genetically characterized revealing 6 novel mutations in the CD40LG gene. Pneumonia was the most common first symptom reported (66%). Initial immunoglobulin levels were variable among patients. Pneumonia (86%), upper respiratory tract infections (70%), neutropenia (70%), and gastrointestinal manifestations (60%) were the most prevalent clinical symptoms throughout life. Thirty-five infectious agents were reported, five of which were not previously described in CD40L deficient patients, representing the largest number of pathogens reported to date in a cohort of CD40L deficient patients. The characterization of the largest cohort of Latin American patients with CD40L deficiency adds novel insights to the recognition of this disorder, helping to fulfill unmet needs and gaps in the diagnosis and management of patients with CD40L deficiency.<br /> (© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)

Details

Language :
English
ISSN :
1573-2592
Volume :
42
Issue :
3
Database :
MEDLINE
Journal :
Journal of clinical immunology
Publication Type :
Academic Journal
Accession number :
34982304
Full Text :
https://doi.org/10.1007/s10875-021-01182-5